163 results on '"Kumada, Hiromitsu"'
Search Results
2. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
- Author
-
Chayama, Kazuaki, Suzuki, Fumitaka, Karino, Yoshiyasu, Kawakami, Yoshiiku, Sato, Ken, Atarashi, Tomofumi, Naganuma, Atsushi, Watanabe, Tsunamasa, Eguchi, Yuichiro, Yoshiji, Hitoshi, Seike, Masataka, Takei, Yoshiyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David L., Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, and Kumada, Hiromitsu
- Published
- 2018
- Full Text
- View/download PDF
3. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
- Author
-
Hayashi, Norio, Nakamuta, Makoto, Takehara, Tetsuo, Kumada, Hiromitsu, Takase, Akiko, Howe, Anita Yee Mei, Ludmerer, Steven W., and Mobashery, Niloufar
- Published
- 2016
- Full Text
- View/download PDF
4. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
- Author
-
Okita, Kiwamu, Izumi, Namiki, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Ikeda, Masafumi, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Kondo, Shunsuke, Nishigaki, Yoichi, Shiomi, Susumu, Ueshima, Kazuomi, Isoda, Norio, Karino, Yoshiyasu, Kudo, Masatoshi, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Makuuchi, Masatoshi, Okusaka, Takuji, Hayashi, Norio, Ohashi, Yasuo, Kumada, Hiromitsu, and The Peretinoin Study Group
- Published
- 2015
- Full Text
- View/download PDF
5. Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts.
- Author
-
Feld, Jordan J., Forns, Xavier, Dylla, Douglas E., Kumada, Hiromitsu, de Ledinghen, Victor, Wei, Lai, Brown, Robert S., Flisiak, Robert, Lampertico, Pietro, Thabut, Dominique, Bondin, Mark, Tatsch, Fernando, Burroughs, Margaret, Marcinak, John, Zhang, Zhenzhen, Emmett, Amanda, and Jacobson, Ira M.
- Subjects
LIVER diseases ,CHRONIC hepatitis C ,LIVER failure ,HEPATITIS C virus ,PLATELET count - Abstract
Chronic hepatitis C virus (HCV) infection has the greatest health impact in patients with advanced liver disease. The direct‐acting antiviral (DAA) regimen glecaprevir/pibrentasvir (G/P) is approved for treatment of HCV‐infected patients without cirrhosis and with compensated cirrhosis. However, events of liver decompensation/failure have been reported in patients treated with protease‐inhibitor–containing DAA regimens, often in patients with advanced liver disease. This study examines the safety of on‐label G/P treatment in patients with compensated cirrhosis (F4 at baseline) with markers of advanced liver disease. Patients with cirrhosis were categorized into 4 subgroups, based on different noninvasive markers of advanced liver disease identified using laboratory measures: platelet count < or ≥ 100 × 109/L, and Child‐Pugh score 5 or 6. Separate analyses were performed using pooled data from clinical trials and from real‐world post‐marketing observational studies. G/P was well tolerated in patients with platelet count ≥100 × 109/L (n = 800), platelet count <100 × 109/L (n = 215), a Child‐Pugh score of 5 (n = 915) and a Child‐Pugh score of 6 (n = 95). In the clinical trial and real‐world cohorts two patients and no patients experienced a serious adverse event (AE) possibly related to study drug, respectively; three patients and no patients experienced an AE of special interest for hepatic decompensation and hepatic failure. This analysis reaffirms G/P's safety profile in indicated patients with compensated cirrhosis, including those with markers of more advanced liver disease. Increasing the number of patients treated with short‐duration G/P therapy may contribute to meeting HCV elimination targets. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan.
- Author
-
Takehara, Tetsuo, Izumi, Namiki, Mochida, Satoshi, Genda, Takuya, Fujiyama, Shigetoshi, Notsumata, Kazuo, Tamori, Akihiro, Suzuki, Fumitaka, Suri, Vithika, Mercier, Renee‐Claude, Matsuda, Takuma, Matsuda, Kana, Kato, Naoya, Chayama, Kazuaki, and Kumada, Hiromitsu
- Subjects
HEPATITIS C ,CHRONIC hepatitis C ,CIRRHOSIS of the liver ,HEPATITIS C virus - Abstract
Background & Purpose: Protease‐free regimens for chronic hepatitis C virus (HCV) infection are safe and effective for persons with either compensated or decompensated cirrhosis. We examined the efficacy and safety of sofosbuvir–velpatasvir in participants with HCV and compensated cirrhosis in Japan. Methods: This was a Phase 3, multi‐center, open‐label study. At 20 sites, 37 individuals with chronic HCV infection of any genotype and compensated cirrhosis received sofosbuvir–velpatasvir (400 mg/100 mg) daily for 12 weeks. Participants were treatment‐naïve or treatment‐experienced with interferon‐based treatments with or without HCV NS3/4A protease inhibitors. Prior exposure with HCV NS5A or NS5B inhibitors was prohibited. The primary study endpoint was sustained virologic response 12 weeks after treatment (SVR12). Results: Among participants, 62% had HCV genotype 1 infection, and 38% had HCV genotype 2. More than three quarters (29/37, 78%) were HCV treatment naïve. All participants (37/37, 100%) achieved SVR12. Seventeen participants (46%) and three participants (8%) had pretreatment resistance‐associated substitutions to HCV NS5A and NS5B nucleoside inhibitors respectively, yet no on‐treatment breakthrough or relapse occurred. Sofosbuvir–velpatasvir for 12 weeks treatment was safe and well tolerated. The most commonly reported adverse events were headache (8%, 3/37) and diarrhea (5%, 2/37). One serious adverse event, patella fracture, occurred and was considered not treatment related. No participants discontinued study treatment due to an adverse event. Three participants (8%) had a Grade 3 laboratory abnormality; all were hyperglycemia. Conclusion: Sofosbuvir–velpatasvir resulted in high SVR rates and was well tolerated among Japanese patients with HCV and compensated cirrhosis. This single‐tablet regimen offers a highly effective, protease‐inhibitor free regimen for treating HCV. ClinicalTrials.gov Identifier: NCT04112303. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
- Author
-
Kobayashi, Mariko, Suzuki, Fumitaka, Akuta, Norio, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kawamura, Yusuke, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Chayama, Kazuaki, Miyakawa, Yuzo, and Kumada, Hiromitsu
- Published
- 2012
- Full Text
- View/download PDF
8. The useful predictors of zinc deficiency for the management of chronic liver disease.
- Author
-
Iritani, Soichi, Kawamura, Yusuke, Muraishi, Nozomu, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, and Kumada, Hiromitsu
- Subjects
LIVER diseases ,ZINC ,CHRONIC diseases ,HEPATITIS C virus ,HEPATITIS B virus - Abstract
Background: Zinc deficiency is likely to occur in chronic liver disease. The aim of this study was to determine the prevalence of zinc deficiency in different types of chronic liver disease and to identify the factors that predicted low serum zinc levels. Methods: The study was an observational single-center design. We obtained the medical records of 666 patients with chronic liver disease whose serum zinc levels had been measured. The cutoff value for zinc deficiency was a serum level < 70 µg/dL. Results: Serum zinc levels in the alcoholic liver disease (ALD) group were significantly lower than in the other groups (hepatitis C virus [HCV], hepatitis B virus [HBV], and other cause) (P < 0.01). The CONUT and ALBI score (r = 0.527, P < 0.01), serum zinc level and ALBI score (r = − 0.607, P < 0.01), and serum zinc level and CONUT score (r = − 0.465, P < 0.01) correlated with each other. The prevalence of zinc deficiency were 44.8%, 63.2%, 86.7%, 97.1%, and 100% in the mALBI grade 1-CONUT normal, CONUT undernutrition, and mALBI grade 2a, 2b, and 3 groups, respectively. Multivariate analysis identified ALD, CONUT score, aspartate aminotransferase, and hemoglobin as significant, independent predictors of zinc deficiency (P < 0.05). Conclusions: This study identified ALD, CONUT score, aspartate aminotransferase, and hemoglobin as predictors of zinc deficiency in chronic liver disease. The rate of zinc deficiency is high even in patients classified as mALBI grade 1, especially in ALD, while caution may be required in those classified as mALBI grade 1-CONUT undernutrition. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients
- Author
-
Ikeda, Kenji, Arase, Yasuji, Kobayashi, Masahiro, Saitoh, Satoshi, Someya, Takashi, Hosaka, Tetsuya, Sezaki, Hitomi, Akuta, Norio, Suzuki, Yoshiyuki, Suzuki, Fumitaka, and Kumada, Hiromitsu
- Published
- 2006
- Full Text
- View/download PDF
10. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis
- Author
-
Ikeda, Kenji, Arase, Yasuji, Kobayashi, Masahiro, Saitoh, Satoshi, Someya, Takashi, Hosaka, Tetsuya, Suzuki, Yoshiyuki, Suzuki, Fumitaka, Tsubota, Akihito, Akuta, Norio, and Kumada, Hiromitsu
- Published
- 2003
- Full Text
- View/download PDF
11. CASE REPORT: Interferon-α for Reinfection with Hepatitis C Virus in Two Patients with Chronic Hepatitis C Who Had Responded to Previous Therapies
- Author
-
Akuta, Norio, Suzuki, Fumitaka, Tsubota, Akihito, Suzuki, Yoshiyuki, Someya, Takashi, Kobayashi, Masahiro, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Miyakawa, Yuzo, and Kumada, Hiromitsu
- Published
- 2003
- Full Text
- View/download PDF
12. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
- Author
-
Suzuki, Fumitaka, Chayama, Kazuaki, Tsubota, Akihito, Akuta, Norio, Someya, Takashi, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Published
- 2001
- Full Text
- View/download PDF
13. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
- Author
-
Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Norio Hayashi, Hiroshi Yotsuyanagi, Hajime Takikawa, Hirohito Tsubouchi, Naoki Hiramatsu, Kumada Hiromitsu, Namiki Izumi, Yasuhiro Asahina, Atsushi Tanaka, Eiji Tanaka, and Yasuhito Tanaka
- Subjects
Hepatology ,business.industry ,Hepatitis C virus ,MEDLINE ,medicine.disease_cause ,Virology ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,030220 oncology & carcinogenesis ,Genotype ,medicine ,030211 gastroenterology & hepatology ,business - Published
- 2016
14. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
- Author
-
Miki, Daiki, Akita, Tomoyuki, Kurisu, Akemi, Kawaoka, Tomokazu, Nakajima, Tomoaki, Hige, Shuhei, Karino, Yoshiyasu, Toyoda, Hidenori, Kumada, Takashi, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Aikata, Hiroshi, Hayes, Clair Nelson, Honda, Koichi, Seike, Masataka, Akuta, Norio, Kobayashi, Mariko, Kumada, Hiromitsu, and Tanaka, Junko
- Subjects
HEPATITIS C virus ,HEPATOCELLULAR carcinoma ,BODY mass index - Abstract
Background: Even though both interferon (IFN)-based and direct-acting antiviral (DAA) therapies against hepatitis C virus (HCV) reduce the risk of hepatocellular carcinoma (HCC), post-sustained virological response (SVR) patients remain at elevated risk of HCC. Methods: A total of 4620 patients who achieved SVR were enrolled in this retrospective cohort study. After excluding patients who had a history of HCC or developed HCC within 1 year and whose follow-up period was less than 1 year and who were positive for HBsAg, we investigated the association between clinical characteristics and HCC development after SVR in the remaining 3771 patients. Results: Median observation period was 41 months. We confirmed known risk factors. In addition, we found that PNPLA3 and HLA-DQB1 polymorphisms were associated with HCC after SVR. Finally, we propose an estimation model for the incidence of HCC after SVR. Based on gender, FIB-4 index, AFP, and PNPLA3 polymorphism, about 18% of all patients were classified as having high risk, with a cumulative incidence rate (CIR) at 5 years of 16.5%. Another 17% were classified as having moderate risk with a CIR of 7.6%. The remaining 65% showed a CIR of 0.5%. The effect of PNPLA3 polymorphism might be more pronounced in patients with lower body mass index (BMI) and without diabetes mellitus compared to those with higher BMI and diabetes mellitus. Conclusions: We demonstrated that PNPLA3 and HLA-DQB1 polymorphisms were associated with HCC after SVR. These findings might be useful to inform risk stratification for HCC surveillance after SVR. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.
- Author
-
Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
CHRONIC hepatitis C ,ESOPHAGEAL varices ,HEPATOCELLULAR carcinoma ,CIRRHOSIS of the liver ,LIVER - Abstract
Aim: The risk of development of hepatocellular carcinoma (HCC) persisted in patients with advanced fibrosis, even after achieving sustained virologic response (SVR). This study aimed to show the advantage of liver stiffness measurement (LSM) at baseline and after SVR to predict HCC occurrence and esophageal varices (EV) exacerbation. Methods: These risks were evaluated in 398 chronic hepatitis C patients without a history of HCC who achieved SVR after direct‐acting antiviral agent and evaluated LSM at least twice during follow up. We defined liver cirrhosis and chronic hepatitis as LSM of ≥12 kPa and <12 kPa, respectively. Results: LSM was significantly correlated with serum fibrosis markers, such as Fib‐4 index and Wisteria floribunda agglutinin‐positive Mac‐2 binding protein, at baseline and SVR at 24 weeks after treatment (SVR24). Five patients received preventive treatment of EV, but no EV bleeding occurred after SVR, and their LSM at baseline and SVR24 was significantly higher than that of other cirrhosis patients. The annual rate of HCC during the first 4 years was 1.5%. LSM in HCC patients tended to decrease after direct‐acting antiviral agent therapies, but significantly higher than that of cirrhosis patients without HCC before and after treatment. Multivariate analysis identified LSM and alpha‐fetoprotein at baseline and LSM at SVR24 as significant independent predictors of HCC. Conclusions: Evaluating LSM not only at baseline, but also SVR24, was found to be useful for the detection of advanced fibrosis patients at high risk of HCC occurrence and EV exacerbation. We recommend focused surveillance of HCC and EV for these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV‐infected Japanese Subjects in Phase 3 CERTAIN‐1 and CERTAIN‐2 Trials.
- Author
-
Suleiman, Ahmed Abbas, Lin, Chih‐Wei, Liu, Wei, Eckert, Doerthe, Mensing, Sven, Burroughs, Margaret, Kato, Koji, Chayama, Kazuaki, Kumada, Hiromitsu, and Oberoi, Rajneet K.
- Subjects
KIDNEY disease diagnosis ,AGE distribution ,ANTIVIRAL agents ,BODY weight ,CHAOS theory ,CHRONIC kidney failure ,DRUG tolerance ,DRUG side effects ,HEMODIALYSIS ,HEPATITIS C ,CIRRHOSIS of the liver ,ORAL drug administration ,TREATMENT effectiveness - Abstract
Glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (Mavyret/Maviret) is an all‐oral, pangenotypic, interferon‐ and ribavirin‐free combination regimen approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of the current analyses was to characterize the pharmacokinetics (PK) of GLE/PIB in HCV‐infected Japanese patients. Data from 332 subjects enrolled in 2 Japan phase 3 trials, CERTAIN‐1 and CERTAIN‐2, were used in the analyses. Pharmacokinetics of GLE/PIB were characterized using a nonlinear mixed‐effects modeling. The analyses evaluated the impact of covariates (concomitant medications and demographic and clinical covariates such as renal impairment, effect of cirrhotic status) on GLE/PIB PK. GLE and PIB PK were described by 1‐ and 2‐compartment models, respectively. Presence of cirrhosis, age, and body weight were identified as significant covariates on GLE/PIB PK. A trend toward higher GLE and PIB exposures in older patients and higher PIB exposures in heavier patients was observed; however, these increases were not considered clinically meaningful. GLE and PIB exposures were higher in HCV‐infected subjects with cirrhosis (Child‐Pugh A; GLE area under the plasma concentration–time curve was 160% higher, and PIB area under the plasma concentration–time curve was 21% higher) compared to subjects without cirrhosis. Renal function (including subjects with end‐stage renal disease with dialysis) had no impact on GLE or PIB exposures. The GLE/PIB dose was well tolerated in the Japanese population, and no dose adjustment is needed for the evaluated intrinsic and extrinsic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy.
- Author
-
Ogasawara, Nobuhiko, Saitoh, Satoshi, Akuta, Norio, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
ESOPHAGEAL varices ,CIRRHOSIS of the liver ,HEPATOCELLULAR carcinoma ,HEPATITIS C virus ,MORTALITY ,HEPATITIS - Abstract
Aim: The long‐term effects of sustained virologic response (SVR) to antiviral therapy on the risk of liver complications, such as exacerbation of esophageal varices (EV), hepatocellular carcinoma (HCC), malignant lymphoma, and liver‐related and overall death in hepatitis C virus (HCV)‐infected patients with liver cirrhosis are not fully known. Methods: These risks were evaluated during long‐term follow up of 457 patients with HCV‐related Child–Pugh Class A liver cirrhosis without history of HCC. Results: The respective cumulative 5‐ and 10‐year rates of EV exacerbation were 2.0% and 3.1%. Multivariate analysis identified the presence of EVs, thrombocytopenia at baseline. and alcohol intake as significant independent predictors of EV exacerbation before and after SVR. The cumulative 5‐ and 10‐year rates of HCC were 6.8% and 10.2%, respectively. Male sex and the presence of EV were significant independent determinants of HCC before and after SVR. Although the cumulative 5‐year HCC recurrence rate was 49.4%, the overall survival rate since HCC was 73.6% at 5 years. The overall survival rates since SVR were 98.7% and 93.6% at 5 and 10 years, respectively. Progression of HCC was the most frequent all‐cause mortality, but none of the patients died of liver decompensation. Male sex and Fibrosis‐4 index of ≥3.0 after SVR were significant and independent predictors of mortality. Conclusion: Patients with HCV remain at risk of HCC for >10 years after achieving SVR, and HCC is the most common cause of mortality. We recommend long‐term surveillance of cirrhotic patients with HCV, even after achieving SVR. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
- Author
-
Sezaki, Hitomi, Suzuki, Fumitaka, Hosaka, Tetsuya, Fujiyama, Shunichirou, Kawamura, Yusuke, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, and Kumada, Hiromitsu
- Subjects
HEPATITIS C virus ,ANTIVIRAL agents ,HEPATITIS - Abstract
Background: Glecaprevir and pibrentasvir (GLE/PIB) are potent antiviral agents for hepatitis C virus (HCV) pan-genotypic infections; however, their clinical effectiveness and safety remain limited in the real-world. This study aimed to evaluate viral responses and the safety of GLE/PIB for patients with chronic HCV-1/2/3 infections during both initial- (Arm A) and re-treatment (Arm B) with all-oral direct-acting antiviral agents (DAAs).Methods: This prospective-observational cohort study included Japanese patients with chronic HCV-1/2/3 infections (n = 271: 183 in Arm A and 83 in Arm B), who had started receiving GLE/PIB. Primary end point was a sustained virological response (SVR) rate at week 12 (SVR12) after the end of GLE/PIB treatment (EOT).Results: SVR12 was achieved by 99.4% of patients (180/181: modified intention-to-treat (mITT) analysis excluding 2 patients lost to follow-up) in Arm A. One patient with an HCV-3b infection who discontinued at week 8 failed to achieve SVR12. SVR12 was achieved by 97.7% of patients (85/87: mITT excluding 1 patient lost to follow-up) in Arm B. Virological relapse occurred in 2 patients with HCV-1b, presenting common 5 loci of resistance-associated substitutions (RASs) including A92 RASs in the NS5A lesion at baseline. Any adverse events (AEs) (grade ≥ 3) occurred in 8 patients (3.0%). 8 patients (3.0%) discontinued due to AEs, however, all of them achieved SVR12.Conclusions: Initial and re-treatment with GLE/PIB are effective and safe for Japanese patients with HCV-1/2/3 in real-life settings. Further studies are required to elucidate the mechanism underlying treatment failures of GLE/PIB to completely eradicate HCV worldwide. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
19. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3
- Author
-
Foster, Graham R., Chayama, Kazuaki, Chuang, Wan Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni B., Hézode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Sheng Nan, Lu, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart K., Strasser, Simone I., Thompson, Alexander J., Toyota, Joji, Paik, Seung Woon, Vierling, John M., Zignego, Anna Linda, Cohen, David, Mcphee, Fiona, Wind Rotolo, Megan, Srinivasan, Subasree, Hruska, Matthew, Myler, Heather, and Portsmouth, Simon D.
- Subjects
virus diseases ,Genotype 2 ,Genotype 3 ,Hepatitis C virus ,Peginterferon alfa-2a ,Peginterferon lambda-1a ,Multidisciplinary - Published
- 2016
20. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.
- Author
-
Wei, Lai, Kumada, Hiromitsu, Perumalswami, Ponni V, Tanwandee, Tawesak, Cheng, Wendy, Heo, Jeong, Cheng, Pin‐Nan, Hwang, Peggy, Mu, Sheng Mei, Zhao, Xu Min, Asante‐Appiah, Ernest, Caro, Luzelena, Hanna, George J, Robertson, Michael N, Haber, Barbara A, and Talwani, Rohit
- Subjects
- *
HEPATITIS C virus , *RESPIRATORY infections , *CHRONIC hepatitis C , *GENOTYPES , *VIRUS diseases - Abstract
Background and Aim: Estimates suggest that in Asia, more than 31 million individuals have hepatitis C virus infection. The present analysis was conducted to assess the efficacy and safety of elbasvir/grazoprevir in Asian participants enrolled in the elbasvir/grazoprevir phase 2/3 clinical trials. Methods: This is an integrated analysis of data from 12 international phase 2/3 clinical trials. Asian participants with chronic hepatitis C virus genotype 1 or 4 infection who received elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks or elbasvir/grazoprevir plus ribavirin for 16 weeks were included in this analysis. The primary end point was sustained virologic response at 12 weeks after completion of therapy (SVR12). Results: Seven hundred eighty Asian participants from 15 countries were included in this analysis. SVR12 was achieved by 756/780 (96.9%) of all participants, including 748/772 (96.9%) of those who received elbasvir/grazoprevir for 12 weeks and 8/8 (100%) of those who received elbasvir/grazoprevir plus ribavirin for 16 weeks. In the genotype 1b‐infected population, the SVR12 rate was 691/709 (97.5%), and there was no impact of age, high baseline viral load, or presence of cirrhosis. The most frequently reported adverse events were nasopharyngitis (8.0%), upper respiratory tract infection (5.4%), and diarrhea (5.2%). Twenty participants receiving elbasvir/grazoprevir for 12 weeks reported a total of 25 serious adverse events, and 7 (0.9%) discontinued treatment because of an adverse event. Conclusion: Elbasvir/grazoprevir administered for 12 weeks is an effective and generally well‐tolerated treatment option for Asian individuals with hepatitis C virus genotype 1b infection. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
- Author
-
Naganuma, Atsushi, Chayama, Kazuaki, Notsumata, Kazuo, Gane, Edward, Foster, Graham R., Wyles, David, Kwo, Paul, Crown, Eric, Bhagat, Abhi, Mensa, Federico J., Otani, Tetsuya, Larsen, Lois, Burroughs, Margaret, and Kumada, Hiromitsu
- Subjects
HEPATITIS C virus ,CHRONIC hepatitis C ,CIRRHOSIS of the liver ,GENOTYPES - Abstract
Background: Chronic hepatitis C virus (HCV) infection with genotypes (GT) 1 and 2 accounts for over 50% of HCV infections globally, including over 97% of all HCV infections in Japan. Here, we report an integrated analysis of efficacy and safety of 8-week treatment with the all-oral, fixed-dose combination of the direct acting antivirals (DAA), glecaprevir and pibrentasvir (G/P), in DAA-naïve Japanese and overseas patients without cirrhosis and with HCV GT1 or GT2 infection.Methods: Data from 899 DAA-naïve patients without cirrhosis and with HCV GT1 or GT2 infection treated with G/P (300/120 mg) for 8 weeks in the six Phase 2 or 3 overseas or Japan-only clinical trials were included. All patients who received ≥ 1 dose of G/P were included in an intent-to-treat (ITT) analysis. The objectives were to evaluate rate of sustained virologic response 12 weeks post-treatment (SVR12) and safety of the 8-week regimen in the ITT population.Results: Overall, SVR12 was achieved by 98.9% (889/899) of DAA-naïve patients without cirrhosis, including 99.2% (597/602) of GT1-infected and 98.3% (292/297) of GT2-infected patients. Less than 1% (2/899) of patients overall and no Japanese patients experienced virologic failure. SVR12 rate was > 97% for patients regardless of baseline characteristics, and common comorbidities or co-medications. Overall, < 1% (2/899) discontinued G/P due to an adverse event (AE) and 1.6% (14/899) of patients experienced a serious AE.Conclusions: 8-week G/P treatment is safe and efficacious in DAA-naive patients without cirrhosis and with HCV GT1 or GT2 infection, demonstrating high SVR12 rates regardless of baseline patient and disease characteristics. CLINICALTRIALS.Gov Identifiers: The trials discussed in this paper were registered with ClinicalTrials.gov as follows: NCT02707952 (CERTAIN-1), NCT02723084 (CERTAIN-2), NCT02243280 (SURVEYOR-I), NCT02243293 (SURVEYOR-II), NCT02604017 (ENDURANCE-1), NCT02738138 (EXPEDITION-2). [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
- Author
-
Takeuchi, Yasue, Akuta, Norio, Sezaki, Hitomi, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
HEPATITIS C ,HEPATITIS C virus - Abstract
Aim: Treatment with all‐oral direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained virologic response (SVR). The aim of this study was to evaluate the safety and treatment efficacy of EBR/GZR in hepatitis C virus (HCV)‐infected patients. Methods: This retrospective cohort study included 147 consecutive patients with chronic HCV genotype 1b infection who were treated with EBR (50 mg) plus GZR (100 mg) once daily for 12 weeks. The rates of SVR at 12 weeks after the end of treatment (SVR12) were evaluated based on patient baseline characteristics. Treatment efficacy was analyzed according to background chronic kidney disease (CKD), and retreatment efficacy in patients who failed to respond to previous DAAs. Results: The SVR12 was 94% (138 of 147 patients), based on intention‐to‐treat analysis. Rates of SVR12 were 97% (131 of 135) and 58% (7 of 12) in cases naïve to DAA treatment and failure to respond to prior DAAs, respectively. The SVR12 rates in patients with CKD stage 4–5 was 100% (8 of 8). All patients (4 of 4 patients) with stage 4–5 and advanced fibrosis (Fibrosis‐4 index ≥3.25) also achieved SVR12. Multivariate analysis that included the above variables identified pretreatment with other DAAs as an independent factor that was significantly and independently associated with non‐SVR12 (odds ratio, 97.5; P < 0.001). Relapsers of first DAAs, excluding the combination of ledipasvir and sofosbuvir, achieved SVR12. Characteristic novel non‐structural protein 5A substitutions were not detected after failure of retreatment with EBR/GZR. Conclusion: Treatment with EBR/GZR was highly efficacious with acceptable safety, even in patients with CKD stage 4–5. Retreatment of relapsers to prior DAAs, excluding ledipasvir and sofosbuvir, achieved SVR12. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
- Author
-
Akuta, Norio, Toyota, Joji, Karino, Yoshiyasu, Ikeda, Fusao, Ido, Akio, Tanaka, Katsuaki, Takaguchi, Koichi, Naganuma, Atsushi, Tomita, Eiichi, Chayama, Kazuaki, Fujiyama, Shigetoshi, Inada, Yukiko, Yoshiji, Hitoshi, Watanabe, Hideaki, Ishikawa, Hiroki, McPhee, Fiona, Noviello, Stephanie, and Kumada, Hiromitsu
- Subjects
FIBROSIS ,ALPHA fetoproteins ,HEPATITIS C treatment ,HEPATITIS C virus ,INFECTION treatment ,PATIENTS - Abstract
Background: In the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). As HCV clearance may improve liver outcomes, we assessed hepatic fibrosis and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post-treatment in UNITY-3.Methods: Treatment-naive or interferon-experienced UNITY-3 patients with HCV GT-1 who received twice-daily DCV-TRIO were assessed for fibrosis [FibroTest; FibroScan; fibrosis-4 index (FIB-4), aspartate-aminotransferase-to-platelet-ratio index] and AFP at baseline and Weeks 4 (FIB-4 only), 12 or 24 post-treatment.Results: Of 217 patients, 99% had GT-1b infection, 46% were aged > 65 years, 21% had compensated cirrhosis, and 26% baseline HCV-RNA > 107 IU/mL. All GT-1b patients treated ≥ 4 weeks achieved SVR12 with (n = 54) or without (n = 144) baseline NS5A polymorphisms associated with DCV resistance (positions 28/30/31/93). Statistically significant post-treatment reductions from baseline were observed for all fibrosis measures and AFP, with numerically greater reductions in cirrhotic patients. FibroTest category improved in 44%, remained stable in 50%, and worsened in 6% of patients; 98% with baseline AFP < 6 μg/L remained < 6 μg/L and 51% with baseline AFP ≥ 6 μg/L were < 6 μg/L post-treatment.Conclusions: DCV-TRIO administered for 12 weeks to Japanese patients with primarily GT-1b infection achieved a high SVR12 rate and resulted in improved measures of hepatic fibrosis and serum AFP that may reduce the risk of future liver disease progression and hepatocellular carcinoma, particularly in those with compensated cirrhosis. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens.
- Author
-
Reddy, K. Rajender, Pol, Stanislas, Thuluvath, Paul J., Kumada, Hiromitsu, Toyota, Joji, Chayama, Kazuaki, Levin, James, Lawitz, Eric J., Gadano, Adrian, Ghesquiere, Wayne, Gerken, Guido, Brunetto, Maurizia R., Peng, Cheng‐yuan, Silva, Marcelo, Strasser, Simone I., Heo, Jeong, Mcphee, Fiona, Liu, Zhaohui, Yang, Rong, and Linaberry, Misti
- Subjects
CLINICAL trials ,HEPATITIS C virus ,DRUG efficacy ,INTERFERONS ,LIVER cancer - Abstract
Abstract: Background & Aims: Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long‐term efficacy and safety of daclatasvir‐based regimens administered during clinical studies. Methods: Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow‐up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non‐responders or responders who relapsed, and characterization of liver disease progression. Results: Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir‐based regimens (follow‐up cut‐off, 13 October 2015); 60% were male, 18% aged ≥65 years, 87% had genotype‐1a (42%) or ‐1b (45%) infection, and 18% had cirrhosis. Median follow‐up from parent study follow‐up Week 12 was 111 (range, 11‐246) weeks. 1329/1489 evaluable patients were SVR12 responders; 1316/1329 maintained SVR until their latest visit. Twelve responders relapsed by (n = 9) or after (n = 3) parent study follow‐up Week 24; one was reinfected. Relapse occurred in 3/842 (0.4%) and 9/487 (2%) responders treated with interferon‐free or interferon‐containing regimens, respectively. Hepatic disease progression and new hepatocellular carcinoma were diagnosed in 15 and 23 patients, respectively. Among non‐responders, emergent non‐structural protein‐5A (NS5A) and ‐3 (NS3) substitutions were replaced by wild‐type sequences in 27/157 (17%) and 35/47 (74%) patients, respectively. Conclusions: SVR12 was durable in 99% of recipients of daclatasvir‐based regimens. Hepatic disease progression and new hepatocellular carcinoma were infrequent. Emergent NS5A substitutions persisted longer than NS3 substitutions among non‐responders. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
- Author
-
Schnell, Gretja, Tripathi, Rakesh, Krishnan, Preethi, Beyer, Jill, Reisch, Thomas, Irvin, Michelle, Dekhtyar, Tatyana, Setze, Carolyn, Rodrigues‐Jr, Lino, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Chayama, Kazuaki, Kumada, Hiromitsu, Collins, Christine, and Pilot‐Matias, Tami
- Abstract
Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536, and with ribavirin for 16 weeks in phase 3 study GIFT II resulted in SVR rates of 72.2% to 91.5%. Overall, 11 out of 125 patients with GT2a and 37 out of 79 patients with GT2b infection experienced virologic failure. The prevalence of baseline polymorphisms in NS3 and NS5A and their the impact on treatment outcome, as well as the development of viral resistance in GT2-infected patients experiencing virologic failure were evaluated by HCV NS3 and NS5A population and clonal sequence analyses. Baseline polymorphisms in NS3 that confer resistance to paritaprevir were rare in both GT2a- and GT2b-infected patients, while baseline polymorphisms in NS5A that confer resistance to ombitasvir were detected in 11.2% and 14.1% of the GT2a- and GT2b-infected patients, respectively. There was no significant impact of baseline polymorphisms on treatment outcome in Japanese patients. The most common treatment-emergent substitutions at the time of virologic failure occurred at amino acid positions 168 in NS3 and 28 in NS5A in both GT2a- and GT2b-infected patients. Although there was a higher rate of virologic failure in patients with GT2b infection, the resistance analyses presented in this report support the conclusion that testing for baseline resistance-associated polymorphisms is not warranted for HCV GT2-infected patients treated with a regimen of ombitasvir/paritaprevir/ritonavir + ribavirin for 16 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Factors predictive of response to interferon-α therapy in hepatitis C virus infection
- Author
-
Mariko Kobayashi, Kumada Hiromitsu, Arase Yasuji, Satoshi Saitoh, Akihito Tsubota, Kenji Ikeda, Isao Koida, Satomi Iwasaki, Michiyo Hashimoto, and Kazuaki Chayama
- Subjects
medicine.medical_specialty ,Univariate analysis ,Hepatology ,biology ,business.industry ,Hepacivirus ,Hepatitis C virus ,Alpha interferon ,Hepatitis C ,medicine.disease ,biology.organism_classification ,medicine.disease_cause ,Gastroenterology ,Internal medicine ,Immunology ,medicine ,Viral disease ,business ,Interferon alfa ,medicine.drug - Abstract
To determine the patient-dependent and virus-related factors that may predict sustained response to interferon-α therapy, we prospectively evaluated 60 consecutive patients with chronic hepatitis C who received a standardized treatment schedule of interferon-α. Twenty-eight patients achieved a long-term sustained remission, 14 patients had temporary responses during treatment but relapsed after completing it and 14 patients did not respond. Four patients dropped out because of severe side effects and were excluded from evaluation of efficacy. Twenty-one variables were chosen as possible predictors of sustained response and were analyzed by means of multi-variate analysis. Variables related to the hepatitis C virus included genotype and concentration in serum before treatment. The former was determined by means of the polymerase chain reaction with genotype-specific primers for genotypes PT, K1, K2a and K2b, which were deduced from nonstructural region 5 of the hepatitis C virus genome. The latter was measured with a competitive polymerase chain reaction technique. Three variables were statistically significant (p
- Published
- 1994
27. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
- Author
-
Sezaki, Hitomi, Suzuki, Fumitaka, Hosaka, Tetsuya, Akuta, Norio, Fujiyama, Shunichiro, Kawamura, Yusuke, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, and Kumada, Hiromitsu
- Subjects
ORAL drug administration ,DRUG efficacy ,CLINICAL trials ,CHRONIC hepatitis C ,AMINOTRANSFERASES - Abstract
Background & Aims It is important to investigate the treatment outcomes in patients excluded from clinical trials ( CTR). The aims of this study were to evaluate the efficacy and safety of a 24-week daclatasvir ( DCV) and asunaprevir ( ASV) therapy for patients with chronic hepatitis C virus ( HCV)-1b infection. Methods A total of 651 HCV-1b patients started dual oral therapy with DCV and ASV for 24 weeks in Toranomon Hospital, Tokyo. Among them, 276 patients met phase III CTR inclusion criteria. The sustained virological response ( SVR) rate after treatment and the adverse events during therapy were compared between CTR-met (patients who met the inclusion criteria) and CTR-unmet (patients who did not meet the inclusion criteria) groups. Results SVR12 was achieved in 87.0% (240/276) and 86.7% (325/375) in CTR-met and CTR-unmet patients respectively. SVR12 rate in simeprevir-experienced patients was 52.9% (9/17). SVR12 rate in patients without resistance-associated variant ( RAV) of NS3 or NS5A loci was 93.7% (416/444). However, the SVR12 rates in patients with NS3-D168, NS5A-L31 and Y93 single RAV at baseline were 55.0% (11/20), 73.9% (17/23) and 65.6% (63/96) respectively. The safety profiles in both CTR-met and CTR-unmet patients were similar. The discontinuation rate as a result of alanine aminotransferase ( ALT) elevation was only 2.9%. Seven (2.5%) patients in CTR-met group and 20 (5.3%) in CTR-unmet group discontinued therapy because of adverse events other than the ALT elevation. Conclusions Dual oral therapy with DCV and ASV in real-life settings was well tolerated with a similar safety profile and achieved similar SVR12 rates as that of CTR. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
- Author
-
Ogata, Fumihiro, Kobayashi, Masahiro, akuta, Norio, Osawa, Mitutaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, Suzuki, Fumitaka, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
ANTIVIRAL agents ,DRUG therapy ,CHRONIC diseases ,HEPATITIS C ,HEPATOCELLULAR carcinoma ,LIVER diseases ,MULTIVARIATE analysis ,GENOTYPES - Abstract
Objectives: There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA. Methods: The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor (n = 707), NS5A inhibitor plus NS5B polymerase inhibitor (n = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir (n = 118), for 12-24 weeks. All patients were free of HCC before and during therapy. Results: In this retrospective study, 22 patients developed HCC during the follow-up (time from the end of antiviral therapy until the last visit: 1.3 years). At 1 and 2 years after completion of the treatment, the cumulative HCC rates for the whole group were 1.8 and 2.3%, respectively, and 1.4 and 1.8%, respectively, for 1,065 patients who showed sustained virological response (SVR). The risk factors for HCC identified by multivariate analysis were hypoalbuminemia, thrombocytopenia, a high α-fetoprotein level, and non-SVR for all patients, and hypoalbuminemia and a high α-fetoprotein level for patients with SVR. Conclusion: Eradication of HCV RNA by direct-acting antiviral regimens might reduce the risk of HCC. Albumin and α-fetoprotein levels are significant risk factors for HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.
- Author
-
Kumada, Hiromitsu, Suzuki, Fumitaka, Kamiya, Naohiro, Orihashi, Madori, Nakayasu, Yoshiyuki, and Yamada, Ichimaro
- Subjects
- *
TELAPREVIR , *INTERFERONS , *HEPATITIS C virus ,HEALTH of patients - Abstract
Aim To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and relapsed patients compared to previous TVR-based triple therapy in Japan. Methods The study group included 35 treatment-naïve (median age, 55 years) and 19 relapsed (median age, 55 years) patients with genotype 1 hepatitis C virus infection. Patients received TVR (750 mg every 8 h) for 12 weeks, in combination with PEG-IFNα-2a and RBV. Results The sustained virological response (SVR24) rates for naïve and relapsed patients were 85.7% (30/35) and 94.7% (18/19), respectively. The discontinuation rate of all study drugs due to adverse events was 5.6% (3/54). Among the 54 patients, grade 3 skin disorders and grade 3 anemia (<8.0 g/dL) were reported in 2 (3.7%) and 6 patients (11.1%), respectively. Although the overall safety profiles were similar for the TVR/PEG-IFNα-2a/RBV and TVR/PEG-IFNα-2b/RBV regimens (previous study), the proportion of patients discontinuing all study drugs due to adverse events was lower in the patients treated with the TVR/PEG-IFNα-2a/RBV regimen (3/54, 5.6%) than TVR/PEG-IFNα-2b/RBV regimen (44/267, 16.5%). Conclusion Telaprevir in combination with PEG-IFNα-2a/RBV provided a high sustained virological response rate for the treatment of genotype 1 hepatitis C virus in both treatment-naïve and relapsed patients in Japan. Telaprevir-based therapy may provide a useful treatment option for patients who are difficult to treat due to NS5A (Y93, L31) and NS3/4A (D168) variants. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
- Author
-
Kumada, Hiromitsu, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Chayama, Kazuaki, Kawada, Norifumi, Okanoue, Takeshi, Itoh, Yoshito, Mochida, Satoshi, Toyoda, Hidenori, Yoshiji, Hitoshi, Takaki, Shintaro, Yatsuzuka, Naoyoshi, Yodoya, Etsuo, Iwasa, Takashi, Fujimoto, Go, Robertson, Michael, Black, Stuart, Caro, Luzelena, Wahl, Janice, and Robertson, Michael N
- Subjects
- *
HEPATITIS C treatment , *HEPATITIS C virus , *DRUG efficacy , *COMBINATION drug therapy , *CIRRHOSIS of the liver - Abstract
Background: Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily conducted in the USA and Europe. We investigated the safety and efficacy of EBR in combination with GZR in Japanese patients with chronic HCV infection, with or without cirrhosis.Methods: The study was conducted in two parts. In part 1, noncirrhotic patients were randomized 1:1 to receive EBR (50 mg) in combination with GZR (50 or 100 mg) once daily for 12 weeks. In part 2, noncirrhotic patients were randomized 3:1 to receive immediate or deferred treatment with EBR (50 mg) and GZR (100 mg, determined in part 1) for 12 weeks; cirrhotic patients received open-label immediate treatment. The primary efficacy end point was the rate of sustained virologic response 12 weeks after completion of the study treatment.Results: In part 1, 63 patients were randomized to receive EBR in combination with GZR at a dose of 50 mg (n = 31) or 100 mg (n = 32). The SVR12 rates were 100% with GZR at a dose of 50 mg and 96.8% with GZR at a dose of 100 mg. Tolerability was similar in both arms. In part 2, 301 noncirrhotic patients were randomized to receive immediate treatment (n = 227) or deferred treatment (n = 74), and 35 cirrhotic patients were enrolled. The SVR12 rates were 96.5% and 97.1% after immediate treatment in noncirrhotic and cirrhotic patients respectively. Safety was generally similar between immediate and deferred treatment.Conclusion: Treatment with EBR in combination with GZR for 12 weeks is effective and well tolerated in Japanese patients with chronic HCV infection. CLINICALTRIALS.Gov Identifier: NCT02203149. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
- Author
-
Kobayashi, Masahiro, Suzuki, Fumitaka, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Abstract
The aim of this study was to assess the rate of development of hepatocellular carcinoma (HCC) in patients who achieved sustained virologic response (SVR) by direct antiviral agents (DAA). We retrospectively evaluated patients who achieved SVR by oral DAA interferon-free regimens (n = 77) (daclatasvir/asunaprevir [n = 67], ombitasvir/paritaprevir/ritonavir [n = 9], and telaprevir [n = 1]) and by pegylated-interferon plus ribavirin (Peg-IFN/RBV, n = 528). In all patients, the background was chronic hepatitis or cirrhosis caused by HCV genotype 1b. During a median follow-up period of 4.0 years, two (2.6%) of DAA-treated patients developed HCC. The 3- and 5-year cumulative HCC development rates were 1.30% and 3.03%, respectively, in the DAA group, and 1.02% and 2.19 % in the Peg-IFN/RBV group ( P not significant). In patients with Fib-4 score of >3.25, the 3-year HCC development rates were 4.35% and 3.95%, whereas those of the 5 year were 9.66% and 8.37%, in the DAA and Peg-IFN/RBV group, respectively. In patients with Fib-4 score of ≤3.25, none of the DAA group developed HCC, whereas 0.48% at 3-year and 1.05% at 5-year of patients of the Peg-IFN/RBV group did. Propensity score analysis using the inverse probability of treatment weights (IPTW) also showed no significant difference in HCC development rate between the two groups. Serum AFP gradually and similarly decreased after initiation of antiviral therapy in both groups. Our data indicate that the HCC risk rate after SVR is similar regardless of whether the latter was achieved by DAA or IFN-based regimens. J. Med. Virol. 89:476-483, 2017. © 2016 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
- Author
-
akuta, Norio, Kobayashi, Masahiro, Suzuki, Fumitaka, Sezaki, Hitomi, Fujiyama, Shunichiro, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Yoshiyuki, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
THERAPEUTIC use of interferons ,ANTIVIRAL agents ,HEPATOCELLULAR carcinoma ,BIOMARKERS ,HEPATITIS C ,LIVER diseases ,MULTIVARIATE analysis ,RNA ,FIBROSIS ,BODY mass index ,TREATMENT effectiveness ,RETROSPECTIVE studies ,GENOTYPES ,DIAGNOSIS - Abstract
Background and Aims: Predictive factors for hepatocarcinogenesis following eradication of hepatitis C virus (HCV) RNA by antiviral therapy with direct-acting antivirals are unknown. Especially the impact of treatment with or without interferon on hepatocarcinogenesis is not clear. Methods: A total of 958 patients with HCV genotype 1-related chronic liver disease and a sustained virological response defined as negative HCV RNA 24 weeks after cessation of antiviral therapy with direct-acting antivirals (triple therapy of NS3/4A protease inhibitor/peginterferon/ribavirin or all-oral combination therapy with NS3/4A protease inhibitor plus NS5A inhibitor) were included in a retrospective study. None of the patients had hepatocellular carcinoma before and during antiviral therapy. Results: In all, 14 patients developed hepatocellular carcinoma during follow-up, and the development rate per 1,000 person-years was 7.35. The cumulative hepatocarcinogenesis rates were 4.2 and 4.2% at the end of 5 and 7 years, respectively. Multivariate analysis identified fibrosis 4 (FIB4) index (= 2.7) and body mass index (= 23.0) as determinants of hepatocarcinogenesis, but they did not identify the treatment regimen. In patients with a FIB4 index = 2.7, the hepatocarcinogenesis rates with the interferon regimen were not different from those for the regimen without interferon, regardless of gender. Conclusion: Liver fibrosis and body mass index, but not treatment regimen, are important predictors of hepatocarcinogenesis following eradication of HCV RNA by direct-acting antivirals. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
- Author
-
Kumada, Hiromitsu, Mochida, Satoshi, Suzuki, Fumitaka, Chayama, Kazuaki, Karino, Yoshiyasu, Nakamura, Keisuke, Fujimoto, Go, Howe, Anita Y. M., Ludmerer, Steve W., and Mobashery, Niloufar
- Subjects
- *
RIBAVIRIN , *NUCLEOSIDES , *ANTIMETABOLITES , *VIRAL hepatitis , *PROTEASE inhibitors - Abstract
Background and Aim Vaniprevir is a macrocyclic hepatitis C virus (HCV) non-structural (NS)3/4A protease inhibitor. The objective of these phase 3 multicenter, open-label trials was to evaluate the safety and efficacy of vaniprevir + peginterferon alfa-2b + ribavirin (PR) in Japanese patients with HCV genotype (GT)1 infection who had previously failed treatment with interferon-based regimens. Methods Japanese patients with chronic HCV GT1 were enrolled. In PN044, patients with previous relapse or virologic breakthrough were randomized to vaniprevir (300 mg twice daily) + PR for 12 weeks followed by PR for another 12 weeks (12-week arm) or vaniprevir + PR for 24 weeks (24-week arm). In PN045, patients with previous partial/null response received vaniprevir + PR for 24 weeks. The primary endpoint was sustained virologic response at 24 weeks after completing treatment (SVR24). Results In PN044 ( n = 51), SVR24 was 92.0% and 96.2% in the 12- and 24-week arms, respectively. In PN045 ( n = 42), SVR24 was 61.9% in all patients and 55.2% in previous null responders. In both studies, vaniprevir + PR was generally safe and well tolerated; the majority of adverse events were mild/moderate and included pyrexia, decreased hemoglobin, headache, nausea, pruritus, and decreased platelet count. Polymorphisms in the HCV NS3 gene at baseline (Y56, Q80, and V170) did not impact treatment outcome. Virologic failure was principally associated with the on-treatment emergence of R155 or D168 mutations. Conclusions Vaniprevir + PR is an effective, well-tolerated treatment for Japanese patients with HCV GT1 infection who failed previous interferon-based treatment. ClinicalTrials. gov Identifier NCT01405937 and NCT01405560 (Protocols PN044 and PN045) [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.
- Author
-
Foster, Graham, Chayama, Kazuaki, Chuang, Wan-Long, Fainboim, Hugo, Farkkila, Martti, Gadano, Adrian, Gaeta, Giovanni, Hézode, Christophe, Inada, Yukiko, Heo, Jeong, Kumada, Hiromitsu, Lu, Sheng-Nan, Marcellin, Patrick, Moreno, Christophe, Roberts, Stuart, Strasser, Simone, Thompson, Alexander, Toyota, Joji, Paik, Seung, and Vierling, John
- Subjects
HEPATITIS C virus ,GENOTYPES ,BACTERIOPHAGE lambda ,HEPATITIS C prevention ,PATIENTS - Abstract
Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda-1a plus ribavirin (Lambda/RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa-2a plus RBV (alfa/RBV) in treatment-naive patients with HCV genotype 2 or 3 infection. Methods: In this multicenter, double-blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome measure was sustained virologic response at post-treatment Week 12 (SVR12). Results: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2 (6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % (95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginterferon alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of flu-like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV. Conclusion: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/RBV. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers.
- Author
-
Ikeda, Kenji, Izumi, Namiki, Tanaka, Eiji, Yotsuyanagi, Hiroshi, Takahashi, Yoshihisa, Fukushima, Junichi, Kondo, Fukuo, Fukusato, Toshio, Koike, Kazuhiko, Hayashi, Norio, Tsubouchi, Hirohito, and Kumada, Hiromitsu
- Subjects
BIOMARKERS ,CHRONIC hepatitis C ,HEPATITIS C virus ,CIRRHOSIS of the liver ,NEEDLE biopsy ,MULTIPLE regression analysis ,HEPATOLOGY ,PATIENTS ,DIAGNOSIS - Abstract
Aim In order to evaluate and judge a fibrotic stage of patients with chronic hepatitis C, multivariate regression analysis was performed using multiple fibrotic markers. Methods A total of 581 patients from eight hepatology units and institutes were diagnosed by needle biopsy as having chronic liver disease caused by hepatitis C virus. Twenty-three variables and their natural logarithmic transformation were employed in the multivariate analysis. Results Multivariate regression analysis finally obtained the following function: z = 2.89 × ln (type IV collagen 7S) (ng/mL) − 0.011 × (platelet count) (×10
3 /mm3 ) + 0.79 × ln (total bilirubin) (mg/dL) + 0.39 × ln (hyaluronic acid) (μg/L) − 1.87. Median values of the fibrotic score of F1 ( n = 172), F2 ( n = 80), F3 ( n = 37) and F4 ( n = 16) were calculated as 1.00, 1.45, 2.82 and 3.83, respectively. Multiple regression coefficient and coefficient of determination were 0.56 and 0.320, respectively. Validation with patient data from other institutions demonstrated good reproducibility of the fibrotic score for hepatitis C ( FSC), showing 1.10 in F1 ( n = 156), 2.35 in F2 ( n = 73), 3.16 in F3 ( n = 36) and 3.58 in F4 ( n = 11). Conclusion A concise multiple regression function using four laboratory parameters successfully predicted pathological fibrotic stage of patients with hepatitis C virus infection. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
36. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients.
- Author
-
Sezaki, Hitomi, Suzuki, Fumitaka, Hosaka, Tetsuya, Akuta, Norio, Fukushima, Taito, Hara, Tasuku, Kawamura, Yusuke, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
CHRONIC hepatitis C ,TELAPREVIR ,DRUG dosage ,RIBAVIRIN ,VIROLOGY ,JAPANESE people ,INTERFERONS ,THERAPEUTICS ,DISEASES - Abstract
Aim To compare the early virological effectiveness, sustained virological response and safety of telaprevir 1500 mg/day with telaprevir 2250 mg/day, when combined in triple therapy with pegylated interferon and ribavirin in Japanese patients with high viral loads of genotype 1 hepatitis C virus. Methods The telaprevir 2250 mg/day and 1500 mg/day groups each contained 60 patients matched by age, sex and history of previous interferon-based treatment. Serum levels of genotype 1 hepatitis C virus RNA, hemoglobin levels, drug adherence and drug discontinuation rates were monitored during and after triple therapy. Results Patients receiving telaprevir 1500 mg/day had significantly lower telaprevir adherence and lower initial ribavirin dose but similar or superior pegylated interferon and ribavirin adherence and a lower rate of telaprevir discontinuation than did those receiving telaprevir 2250 mg/day. The early virological responses and sustained virological response rates were similar in both groups. Hemoglobin levels decreased to a greater extent in patients treated with telaprevir 2250 mg/day. Conclusion Compared to triple therapy including telaprevir 2250 mg/day, that including telaprevir at a reduced dose of 1500 mg/day was associated with lower rates of anemia and similar antiviral efficacy. Such a regimen may meaningfully improve sustained virological response rates, especially among female and elderly Japanese patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
37. Interleukin 28 B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.
- Author
-
Shakado, Satoshi, Sakisaka, Shotaro, Okanoue, Takeshi, Chayama, Kazuaki, Izumi, Namiki, Toyoda, Joji, Tanaka, Eiji, Ido, Akio, Takehara, Tetsuo, Yoshioka, Kentaro, Hiasa, Yoichi, Nomura, Hideyuki, Seike, Masataka, Ueno, Yoshiyuki, and Kumada, Hiromitsu
- Subjects
INTERLEUKINS ,SINGLE nucleotide polymorphisms ,RIBAVIRIN ,HEALTH outcome assessment ,HEPATITIS C virus ,PUBLIC health - Abstract
Aim This study evaluated the efficacy of interferon plus ribavirin and examined whether interleukin 28B ( IL28B) polymorphism influenced treatment outcome in Japanese patients with hepatitis C virus ( HCV)-related liver cirrhosis ( LC). Methods Fourteen collaborating centers provided details of 261 patients with HCV-related LC undergoing treatment with interferon plus ribavirin. Univariate and multivariate analyses were used to establish which factors predicted treatment outcome. Results Eighty-four patients (32.2%) achieved a sustained virological response ( SVR). SVR rates were 21.6% (41/190) in patients with HCV genotype 1 with high viral load ( G1H) and 60.6% (43/71) in patients with non- G1H. In patients with non- G1H, treatment outcome was effective irrespective of IL28B polymorphism. In those with G1H, SVR was achieved in 27.1% of patients with the IL28B rs8099917 TT allele compared with 8.8% of those with the TG/ GG alleles ( P = 0.004). In patients with G1H having TT allele, treatments longer than 48 weeks achieved significantly higher SVR rates than treatments less than 48 weeks (34.6% vs 16.4%, P = 0.042). In patients with G1H having TG/ GG alleles, treatments longer than 72 weeks achieved significantly higher SVR rates than treatments less than 72 weeks (37.5% vs 4.1%, P = 0.010). Conclusion Interferon plus ribavirin treatment in Japanese patients with non- G1H HCV-related LC was more effective than those with G1H and not influenced by IL28B polymorphism. In those with G1H, IL28B polymorphism may predict SVR and guide treatment duration: SVR rates were higher in those with the TT allele treated for more than 48 weeks and those with the TG/ GG alleles treated for more than 72 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
- Author
-
Izumi, Namiki, Hayashi, Norio, Kumada, Hiromitsu, Okanoue, Takeshi, Tsubouchi, Hirohito, Yatsuhashi, Hiroshi, Kato, Mai, Ki, Rito, Komada, Yuji, Seto, Chiharu, and Goto, Shoichiro
- Subjects
THERAPEUTIC use of interferons ,RIBAVIRIN ,HEPATITIS C treatment ,HEPATITIS C virus ,DISEASE relapse ,PATIENTS - Abstract
Background: Efficacy of available therapies for patients with HCV who have previously failed treatment is limited. Two Phase III, open-label trials in Japan investigated efficacy and safety of simeprevir and peginterferon-α-2a/ribavirin (PR) combination therapy in treatment-experienced patients with genotype 1 HCV infection. Methods: In CONCERTO-2, prior non-responders to IFN-based therapy ( N = 106) received simeprevir (TMC435) 100 mg QD with PR for 12 (SMV12, n = 53) or 24 weeks (SMV24, n = 53) followed by response-guided therapy (RGT) with PR for 12/36 (SMV12) or 0/24 (SMV24) weeks. In CONCERTO-3, relapsers after IFN-based therapy ( N = 49) received simeprevir 100 mg QD with PR for 12 weeks followed by RGT with PR for 12/36 weeks. Primary endpoints were the rates of sustained virologic response 12 weeks after treatment end (SVR12). Results: SVR12 rates were 52.8 % (SMV12) and 35.8 % (SMV24) for prior non-responders, and 95.9 % for prior relapsers (SMV12; p ≤ 0.0001 vs null hypothesis, respectively). Most prior non-responders (SMV12: 81.1 %; SMV24: 73.6 %) and prior relapsers (95.9 %) met RGT criteria and completed PR to Week 24. Of these, 60.5 %, 48.7 %, and 95.7 %, respectively, achieved SVR12. Viral breakthrough occurred in 13.2 % (SMV12) and 11.3 % (SMV24) of prior non-responders; no viral breakthrough occurred in prior relapsers. Viral relapse occurred in 38.6 % (SMV12) and 51.1 % (SMV24) of prior non-responders and 8.2 % of prior relapsers. Simeprevir with PR was generally well tolerated in both studies. Conclusion: Re-treatment with 12 weeks of simeprevir QD with PR provided high SVR in treatment-experienced patients with chronic HCV genotype 1 infection, and allowed most patients to complete treatment in 24 weeks. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.
- Author
-
Arase, Yasuji, Kobayashi, Mariko, Kawamura, Yusuke, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Akuta, Norio, Kobayashi, Masahiro, Sezaki, Hitomi, Saito, Satoshi, Hosaka, Tetsuya, Ikeda, Kenji, Kumada, Hiromitsu, and Kobayashi, Tetsuro
- Abstract
ABSTRACT The aim of this retrospective cohort study was to assess the cumulative incidence and predictive factors for intracerebral hemorrhagic stroke after the termination of interferon (IFN) therapy in Japanese patients with hepatitis C virus (HCV). A total of 4,649 HCV-positive patients treated with IFN were enrolled. The primary goal is the first onset of intracerebral hemorrhagic stroke. The mean observation period was 8.0 years. Evaluation was performed using the Kaplan-Meier method and the Cox proportional hazard model. A P-value of less than 0.05 was considered statistically significant. A total of 28 developed intracerebral hemorrhagic stroke. The cumulative incidence of intracerebral hemorrhagic stroke was 0.3% at 5 years, 0.8% at 10 years, and 1.7% at 15 years. Intracerebral hemorrhagic stroke occurred when patients had age increments of 10 years (hazard ratio: 2.77; 95% confidence interval (CI) 1.48-5.18; P = 0.001), hypertension (hazard ratio: 2.30; 95% CI 1.09-4.83; P = 0.021), liver cirrhosis (hazard ratio: 4.50; 95% CI 2.07-9.78; P < 0.001), and HCV non-clearance (hazard ratio: 3.22; 95% CI 1.22-8.53; P = 0.018). On the intracerebral hemorrhagic stroke based on the difference of liver fibrosis and efficacy of IFN therapy, HCV clearance reduced to 24.3% (1/4.11) compared to HCV non-clearance in cirrhotic patients ( P = 0.040). In conclusion, HCV clearance reduced the development of intracerebral hemorrhagic stroke. In particular, HCV clearance reduced intracerebral hemorrhagic stroke to about one-fourth in cirrhotic patients. J. Med. Virol. 86:169-175, 2014. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
40. Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy.
- Author
-
Seko, Yuya, akuta, Norio, Suzuki, Fumitaka, Kawamura, Yusuke, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
AMINO acids ,SUBSTITUTION reactions ,HEPATITIS C virus ,LIPID metabolism ,CARCINOGENESIS ,INTERFERONS ,RIBAVIRIN - Abstract
Background: Substitution of amino acid 70 and/or 91 in the core region of hepatitis C virus (HCV) genotype 1b (HCV-1b) is an important predictor of hepatocellular carcinoma (HCC), but its impact on HCC in nonresponders to interferon (IFN) and ribavirin (RIB) combination therapy is not clear. Methods: A total of 292 patients with HCV-1b-related chronic liver disease who did not achieve a sustained virological response to 24-48 weeks of IFN+RIB combination therapy were included in a follow-up study to investigate the risk factors for HCC. Results: Sixteen patients developed HCC during the follow-up. The cumulative HCC rates were 5.0, 13.1 and 16.9% at the end of 3, 5 and 7 years, respectively. Multivariate analysis identified substitution of core amino acid 70 (Gln70/His70; hazard ratio 4.64, p = 0.018) and low serum levels of high-density lipoprotein cholesterol (<50 mg/dl; hazard ratio 9.35, p = 0.041) as determinants of HCC. Gender, stage of fibrosis and interleukin-28B showed no such relationship. Conclusions: Amino acid substitution in the core region of HCV-1b and low serum levels of high-density lipoprotein cholesterol are significant and independent predictors of HCC in nonresponders to IFN+RIB combination therapy. These results emphasize the importance of viral and lipid metabolic factors in the development of HCC after combination therapy. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
41. Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis.
- Author
-
akuta, Norio, Suzuki, Fumitaka, Seko, Yuya, Kawamura, Yusuke, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
HEPATITIS C treatment ,DRUG efficacy ,CARCINOGENS ,RIBAVIRIN ,HEPATITIS C virus ,CIRRHOSIS of the liver ,BIOCHEMIC medicine - Abstract
Objective: Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear. Methods: In study 1, in 157 consecutive patients with HCV-related compensated cirrhosis, treatment efficacy with interferon plus ribavirin therapy was evaluated for 48 weeks of HCV genotype 1b (HCV-1b) or 24 weeks of HCV-2a/2b. In study 2, in 185 consecutive patients with HCV-related compensated cirrhosis, who showed no sustained virological response following the first course of interferon monotherapy, hepatocarcinogenesis rates were evaluated according to the additional treatment, and they were classified into three groups: no treatment, interferon monotherapy, and ribavirin combination therapy. Results: In study 1, in HCV-1b, rates of sustained virological response and sustained biochemical response were 21 and 56%, respectively. In HCV-2a/2b, rates of sustained virological response and sustained biochemical response were 70 and 78%, respectively. In HCV-1b, sustained biochemical response rates were significantly higher than those of sustained virological response. In study 2, the hepatocarcinogenesis rates in ribavirin combination therapy were significantly lower than those in interferon monotherapy and no treatment, respectively. Conclusion: Ribavirin combination therapy for HCV-related compensated cirrhosis reduces the risk of hepatocarcinogenesis in comparison with interferon monotherapy, and higher rates of sustained biochemical response might be associated with lower hepatocarcinogenesis rates. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
42. Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.
- Author
-
Akuta, Norio, Suzuki, Fumitaka, Hirakawa, Miharu, Kawamura, Yusuke, Yatsuji, Hiromi, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Chayama, Kazuaki, Nakamura, Yusuke, and Kumada, Hiromitsu
- Subjects
HEPATITIS C virus ,THERAPEUTIC use of amino acids ,BIOLOGICAL variation ,RIBAVIRIN ,OLIGOPEPTIDES ,TREATMENT effectiveness ,VIRAL disease treatment ,MULTIVARIATE analysis ,THERAPEUTICS - Abstract
Objectives: Genetic variation near the IL28B gene and substitution of aa 70 and 91 in the core region of HCV-1b are useful as predictors of treatment efficacy to telaprevir/pegylated interferon (PEG-IFN)/ribavirin, but its impact on viral dynamics is not clear. Methods: This study investigated predictive factors of viral dynamics during 12- or 24-week regimen of triple therapy in 80 Japanese adults infected with HCV-1b. Results: After 24 h of commencement of treatment, the proportion of patients with Arg70 and Leu91 substitutions in the core region who showed ≥3.0 log drop in HCV RNA level was significantly higher than that of patients with Gln70 (His70) and/or Met91. At 8 and 12 weeks, HCV RNA loss rate of patients with rs8099917 genotype TT near IL28B gene was significantly higher than that of patients with non-TT. Multivariate analysis identified substitution of aa 70 and 91 as a predictor of ≥3.0 log fall in HCV RNA level at 24 h (Arg70 and Leu91) and SVR (Arg70), and rs8099917 (TT) as a predictor of HCV RNA loss at 12 weeks and SVR. Conclusions: This study identified genetic variation near IL28B gene and aa substitution of the core region as predictors of viral dynamics during triple therapy. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
43. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
- Author
-
Miyashita, Miyuki, Ito, Takayoshi, Sakaki, Masashi, Kajiwara, Atsushi, Nozawa, Hisako, Hiroishi, Kazumasa, Kobayashi, Mariko, Kumada, Hiromitsu, and Imawari, Michio
- Subjects
GENETIC polymorphisms ,CYCLOOXYGENASE 2 ,PROMOTERS (Genetics) ,INFLAMMATION ,FIBROSIS ,APOPTOSIS ,CARCINOGENESIS ,CHRONIC hepatitis C - Abstract
. Cyclooxygenase ( COX)-2 is involved in inflammation, anti-apoptosis and carcinogenesis. The -1195GG genotype of single nucleotide polymorphism (SNP) in COX-2 promoter was associated with low platelet counts in patients with chronic hepatitis C. Polymorphism of patatin-like phospholipase domain-containing protein 3 ( PNPLA3) gene (rs738409 C>G) have been reported to be associated with cirrhosis, and the major genotype of SNPs near interleukin (IL)28B are related to viral clearance. The present study was designed to assess the contribution of these SNPs to disease progression in patients with chronic hepatitis C. The study enrolled 220 Japanese patients with chronic hepatitis C. Three SNPs, -1195 COX-2, PNPLA3 and IL28B (rs8099917), were genotyped in order to analyze their association with hepatic fibrosis and inflammation. The -1195GG genotype in COX-2 was associated with advanced fibrosis and higher levels of inflammation in the liver tissues. The major genotype of IL28B was also associated with advanced fibrosis, but the polymorphism of PNPLA3 was neither associated with fibrosis nor inflammation. Multivariate analysis showed that -1195GG in COX-2 is an independent factor associated with advanced fibrosis, while the major genotype of IL28B and HCV genotype 2 were other independent factors. In conclusion, the -1195GG genotype in COX-2 is a genetic marker for liver disease progression, while the PNPLA3 genotypes are not associated with disease progression in Japanese patients with chronic hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
44. Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy.
- Author
-
Akuta, Norio, Suzuki, Fumitaka, Hirakawa, Miharu, Kawamura, Yusuke, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Chayama, Kazuaki, Nakamura, Yusuke, and Kumada, Hiromitsu
- Subjects
HEPATITIS C virus ,AMINO acids ,INTERLEUKINS ,INTERFERONS ,RIBAVIRIN ,COMBINATION drug therapy - Abstract
Objective: To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b). Methods: This study investigated pretreatment predictors, including viral- (aa substitutions in core aa 70/91 and NS5A-ISDR/IRRDR) and host-related factors (genetic variation near IL28B gene), to 48-week IFN/ribavirin in 490 Japanese adults infected with HCV-1b. Results: The proportion of patients who showed end-of-treatment response (ETR), sustained virological response (SVR), and SVR after ETR was 76, 54, and 76%, respectively. There was a significant positive correlation between the number of aa substitutions in ISDR and those in IRRDR. Concerning the substitution of core aa 91, the number of aa substitutions in ISDR/IRRDR of patients with Leu91 was significantly higher than that of patients with Met91. Furthermore, levels of viremia were influenced by aa substitutions in core aa 91 and ISDR/IRRDR. By multivariate analysis, rs8099917 genotype was an important predictor of ETR and SVR. With regard to viral factors, core aa 70/91 was an important predictor of ETR, and SVR after ETR. ISDR was an important predictor of SVR, and SVR after ETR. Conclusion: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
45. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.
- Author
-
Arase, Yasuji, Kobayashi, Mariko, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Kawamura, Yusuke, Akuta, Norio, Imai, Norihiro, Kobayashi, Masahiro, Sezaki, Hitomi, Matsumoto, Naoki, Saito, Satoshi, Hosaka, Tetsuya, Ikeda, Kenji, Kumada, Hiromitsu, Ohmoto, Yuki, Amakawa, Kazuhisa, Hsieh, Shiun Dong, Ogawa, Kyoko, Tanabe, Maho, and Tsuji, Hiroshi
- Subjects
LIVER cancer ,OLDER patients ,HEPATITIS C virus ,ETIOLOGY of diseases ,PROPORTIONAL hazards models ,FATTY liver - Abstract
Aim: Malignancies that include hepatocellular carcinoma often occurred in patients with chronic liver disease. The aim of this retrospective match control study was to assess the cumulative development incidence and predictive factors for total malignancies in elderly Japanese patients with non-alcoholic hepatic diseases (NAFLD) or hepatitis C virus (HCV). Methods: A total of 1600 NAFLD patients with age of ≥60 years were enrolled, and 1600 HCV patients with age of ≥60 years were selected as control by matching 1:1 with NAFLD group for age, sex, and follow-up period. The primary goal is the first development of malignancies. Evaluation was performed by the use of the Wilcoxon rank sum test, the Kaplan-Meier method, and Cox proportional hazard model. The mean observation period is 8.2 years in both NAFLD and HCV group, respectively. Results: The number of patients with the development of malignancies was 167 in the NAFLD group and 395 in the HCV group. The 10th development rate of malignancies was 13.9% in the NAFLD group and 28.2% in the HCV group (risk ratio 2.27; P < 0.001). The incident rates of hepatocellular carcinoma in all the malignancies were 6.0% (10/167) in the NAFLD group and 67.6% (267/395) in the HCV group ( P < 0.001). The malignancies in the NAFLD group were observed in the following order: gastric cancer 34 cases (20.4%) > colon cancer 31 cases (18.6%) > prostate cancer 21 cases (12.6%). Conclusions: The incident rates of hepatocellular carcinoma in all the malignancies were approximately 6% in the NAFLD group and two-thirds in the HCV group. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
46. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.
- Author
-
Miki, Daiki, Ochi, Hidenori, Nelson Hayes, C., Abe, Hiromi, Yoshima, Tadahiko, Aikata, Hiroshi, Ikeda, Kenji, Kumada, Hiromitsu, Toyota, Joji, Morizono, Takashi, Tsunoda, Tatsuhiko, Kubo, Michiaki, Nakamura, Yusuke, Kamatani, Naoyuki, and Chayama, Kazuaki
- Subjects
LOCUS (Genetics) ,GENETIC research ,LIVER cancer ,HEPATITIS C virus ,CANCER research - Abstract
Chronic viral hepatitis is the most important risk factor for progression to hepatocellular carcinoma (HCC). To identify genetic risk factors for progression to HCC in individuals with chronic hepatitis C virus (HCV), we analyzed 467,538 SNPs in 212 Japanese individuals with chronic HCV with HCC and 765 individuals with chronic HCV without HCC. We identified one intronic SNP in the DEPDC5 locus on chromosome 22 associated with HCC risk and confirmed the association using an independent case-control population (710 cases and 1,625 controls). The association was highly significant when we analyzed the stages separately as well as together (rs1012068, P
combined = 1.27 × 10?13 , odds ratio = 1.75). The significance level of the association further increased after adjustment for gender, age and platelet count (P = 1.35 × 10?14 , odds ratio = 1.96). Our findings suggest that common variants within the DEPDC5 locus affect susceptibility to HCC in Japanese individuals with chronic HCV infection. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
47. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus.
- Author
-
Arase, Yasuji, Suzuki, Fumitaka, Kobayashi, Mariko, Suzuki, Yoshiyuki, Kawamura, Yusuke, Matsumoto, Naoki, Akuta, Norio, Imai, Norihisa, Kobayashi, Masahiro, Sezaki, Hitomi, Saito, Satoshi, Hosaka, Tetsuya, Ikeda, Kenji, Kumada, Hiromitsu, Ohmoto, Yuki, Amakawa, Kazuhisa, Tsuji, Hiroshi, Hsieh, Shium Dong, and Kobayashi, Tetsurou
- Subjects
DRUG efficacy ,DIABETES complications ,HYPOGLYCEMIC agents ,LIVER diseases ,HEPATITIS C virus ,CD26 antigen ,RETROSPECTIVE studies ,MEDICATION safety - Abstract
Diabetes is present in patients with chronic liver disease caused by hepatitis C virus (HCV). The aim of this case-control study is to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with chronic liver disease caused by HCV. Sixteen HCV positive patients with T2DM treated by sitagliptin were retrospectively enrolled. These patients were given sitagliptin between December 2009 and January 2010. Another 16 HCV patients with T2DM treated only with diet and excise for 48 weeks were selected as the control group. Serum levels of fasting plasma glucose (FPG), hemoglobin A1C (HbA1C), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured before and 12, 24, 36 and 48 weeks after the initiation of treatment. In the sitagliptin group, the average HbA1C level decreased approximately 0.8% at 48 weeks after the initiation of sitagliptin. Next, the average FPG level decreased approximately 20 mg/dL during follow up after the initiation of sitagliptin. All the patients were able to take sitagliptin of 50 mg/day without reduction because of sitagliptin-related side-effects. On the other hand, in the control group, the average HbA1C and FPG level did not change with statistical significance during follow up of 48 weeks. Regarding aminotransferase, there were no significant changes of average AST and ALT level during follow up of 48 weeks in both the sitagliptin group and control group. Our results indicate that sitagliptin is effective and safe for the treatment of T2DM complicated with HCV positive chronic liver disease. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
48. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.
- Author
-
Ikeda, Kenji, Kobayashi, Masahiro, Seko, Yuya, Imai, Norihiro, Hirakawa, Miharu, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, and Kumada, Hiromitsu
- Subjects
INTERFERONS ,LIVER cancer ,CATHETER ablation ,CANCER relapse ,HEPATITIS C virus ,RNA ,VIROLOGY ,MULTIVARIATE analysis - Abstract
Since hepatocellular carcinoma often recurs after surgical resection or radiofrequency ablation, we analyzed a retrospective large cohort of patients with small hepatocellular carcinoma caused by hepatitis C virus (HCV). Among 379 patients with HCV RNA-positive small hepatocellular carcinoma (multiple up to three nodules, 3 cm or less each), 77 received interferon-alpha injection and 302 received no anti-viral therapy. Four patients (5.2%) attained sustained virological response (SVR). Cumulative recurrence rates in the treated and untreated groups were 41.1% and 57.5% at the end of the third year, and 63.0% and 74.5% at the fifth year, respectively ( P = 0.013). Fifth year-recurrence rates in treated group were 25.0% in SVR, 85.7% in biochemical response, 71.1% in no response, and 46.7% in patients with continuous administration. When four patients with SVR were excluded, recurrence rates in short-term interferon therapy (<2 years) and long-term therapy (≥2 years) were 46.2% and 39.3% at the third year, and 66.2% and 57.4% at the fifth year, respectively ( P = 0.012). Multivariate analysis showed that long-term interferon therapy significantly decreased recurrence rate (hazard ratio for interferon <2 years 0.80, interferon ≥2 years 0.60, P = 0.044), after adjustment with background covariates including indocyanine green retention rate ( P = 0.018), alpha-fetoprotein ( P = 0.051), and tumor treatment ( P = 0.066). A long-term administration of low-dose interferon significantly decreased recurrence of hepatocellular carcinoma after surgical resection or radiofrequency ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
49. Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases.
- Author
-
Akuta, Norio, Suzuki, Fumitaka, Arase, Yasuji, Hirakawa, Miharu, Kawamura, Yusuke, Yatsuji, Hiromi, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Ikeda, Kenji, and Kumada, Hiromitsu
- Subjects
GENETIC polymorphisms ,HEPATITIS C ,RIBAVIRIN ,COMBINATION drug therapy ,CASE studies ,GENETIC research - Abstract
Objective: In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2. Methods: 7 patients infected with genotype 2 at a high viral load and who did not achieve a sustained virological response (SVR) with the first course of 24-week IFN plus ribavirin were recruited into the study protocol with a total of 48 weeks of peginterferon plus ribavirin therapy. Results: SVR was achieved in 5 of 7 patients (71%). All 4 patients (100%) who were in relapse with the first course achieved SVR. Only 1 of 3 patients (33%) who had a non-virological response (NVR) with the first course achieved SVR. All 4 patients who had an early virological response (EVR) with the first course achieved EVR and SVR. Two of 3 patients who had no EVR with the first course also did not achieve EVR and SVR. One patient who had no EVR or a NVR during the first course achieved EVR and SVR with the second course. Conclusions: Our results suggest that extending combination therapy for genotype 2 chronic hepatitis C might be useful for patients who relapse following 24-week combination therapy. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
50. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009).
- Author
-
Namiki, Izumi, Nishiguchi, Shuhei, Hino, Keisuke, Suzuki, Fumitaka, Kumada, Hiromitsu, Itoh, Yoshihito, Asahina, Yusuhiro, Tamori, Akihiro, Hiramatsu, Naoki, Hayashi, Norio, and Kudo, Masatoshi
- Subjects
CONFERENCES & conventions ,HEPATITIS C ,DIAGNOSIS ,LIVER cancer ,HEPATITIS C virus - Abstract
The consensus meeting for the diagnosis, management and treatment for hepatitis C was held in 45
th annual meeting for the Japan Society of Hepatology (JSH) in June 2009 where the recommendations and informative statements were discussed including organizers and presenters. The Several important informative statements and recommendations have been shown. This was the fourth JSH consensus meeting of hepatitis C, however, the recommendations have not been published in English previously. Thus, this is the first report of JSH consensus of hepatitis C. The rate of development of hepatocellular carcinoma (HCC) in HCV-infected patients in Japan is higher than in the USA, because the average age of the HCV-infected patients is greater and there are more patients with severe fibrosis of the liver than in the USA. In Japan, more than 60% of HCV-infected patients are genotype 1b infection, and they show lower response to perinterferon and ribavirin combination treatment. To improve the response rate is also an important issue in our country. To establish the original recommendations and informative statements to prevent the development of HCC is a very important issue in Japan. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.